Abstract: Objective To investigate the effect of Dengzhan Shengmai Capsule combined with perindopril tert butylamine on chronic heart failure. Methods Selected 120 cases of patients with who chronic heart failure were treated in our hospital from January 2020 to December 2020, divided into two groups according to the treatment method. The control group was treated with perindopril tert butylamine alone, and the observation group was treated with Dengzhan Shengmai Capsule. Cardiac function and symptoms were evaluated in both groups, and high mobility group1 (HMGB1), β- Endorphin（β-EP), soluble glycation end product receptor (sRAGE), N-terminal precursor of B-type brain natriuretic peptide (NT-proBNP) and transformant factor-β1（TGF-β1). Results After treatment, LVESD, SV, LVEDD, 6 min walking distance and LVEF in the two groups were significantly improved (P<0.05), and LVESD, SV, LVEDD, 6-min walking distance and LVEF in the observation group were significantly better than those in the control group (P<0.05). After treatment, the scores of asthma, palpitations, shortness of breath, edema of lower limbs, chest tightness and chest pain, and chilly cold limbs in the two groups were significantly reduced (P<0.05), and the scores of asthma, palpitations, shortness of breath, edema of lower limbs, chest tightness and chest pain, and chilly cold limbs in the observation group were significantly lower than those in the control group (P<0.05). After treatment, serum levels of HMGB1, sRAGE, NT proBNP β- EP and TGF- β 1he were significantly decreased (P<0.05). Conclusion Dengzhan Shengmai Capsule combined with perindopril tert butylamine had a significant effect in chronic heart failure, which could improve the cardiac function and TCM syndrome, and reduce the serum levels of HMGB 1, sRAGE, NT-proBNP, β -EP, and TGF- β 1.

Key words: Dengzhan Shengmai capsule, perindopril tert butylamine, chronic heart failure, curative effect